



The 2022 Digital Learning Journey on Thyroid Disorders

VIDEO INTERVIEW**LAUNCH DATE 30 April 2022**

Amiodarone and Thyroid

OVERVIEW

Although amiodarone is regarded as a highly effective anti-arrhythmic agent, its use may lead to alterations in thyroid gland function and/or thyroid hormone metabolism, because of its rich iodine content. Patients treated with amiodarone may manifest different altered thyroid dysfunctions, going from overt hypothyroidism to overt hyperthyroidism and thyrotoxicosis. This may also worsen the cardiac arrhythmia. Clinicians working with patients on amiodarone should therefore be well-educated to suspect, recognize, diagnose and appropriately treat patients with amiodarone-induced thyroid disease. In this video interview, Prof Salman Razvi, a key opinion leader on thyroid disorders and their relationship with cardiovascular disease, will discuss about difficult-to-solve clinical dilemma.

LEARNING OBJECTIVES

- Define the impact of amiodarone treatment on thyroid physiology
- Be able to identify and manage amiodarone-induced thyroid disorders

TARGET AUDIENCE

Endocrinologists, Cardiologists, Internal Medicine Specialists, General Practitioners

FACULTY

Salman Razvi

Senior Lecturer
Endocrinology department,
Newcastle University,
Newcastle upon Tyne, UK



LANGUAGE

English with subtitles in Spanish and Mandarin Chinese

This independent educational program is made possible thanks to an educational grant received from Merck Healthcare KGaA, Darmstadt, Germany.

